• About
    • Company
    • CEO Message
    • Leadership
    • History
    • Vision & Mission
  • Technology
    • Dual Action Therapy(DAT) Platform
  • Pipeline
    • Pipeline Schedule
  • Clinical Trials
    • Clinical Trials
  • PR/IR
    • Notice
    • Publication
    • Tech, Transfer
    • License Out
  • Contact
    • Career
    • Contact Us
    • Location
언어선택
  • About
    • Company
    • CEO Message
    • Leadership
    • History
    • Vision & Mission
  • Technology
    • Dual Action Therapy(DAT) Platform
  • Pipeline
    • Pipeline Schedule
  • Clinical Trials
    • Clinical Trials
  • PR/IR
    • Notice
    • Publication
    • Tech, Transfer
    • License Out
  • Contact
    • Career
    • Contact Us
    • Location
  • PR/IR
  • Publication
PR/IR
SCROLL
  • Notice
  • Publication
  • Tech, Transfer
  • License Out
Publication
  • PAPER
    Hyperphosphorylated tau targeting human serum albumin Fusion protein as therapeutics for Alzheimer&r..
    12.09.2024
  • PATENT
    Methods of decreasing amyloid beta (Aβ) plaque deposition and hyperphosphorylated tau plaque de..
    10.24.2024
  • PAPER
    Human serum albumin fusion protein as therapeutics for targeting amyloid beta in Alzheimer’s d..
    01.22.2022
  • PATENT
    Method for Treating Shingles with N-Methanocarbathymidine (N-MCT)
    08.01.2018
1
L&J BIO
Address
US   25 West Watkins Mill Road Suite C, Gaithersburg, MD 20878, USA

KR   A-711, 712, Beobwon-ro, Songpa-gu, Seoul, 05854, Republic of Korea
TEL

US +1-301-355-4131

KR +82-2-527-8379

E-mail
contact@lnjbio.com

Copyright (C) L & J BIO. All Rights Reserved